MicroRNA‑708‑5p affects proliferation and invasion of osteosarcoma cells by targeting URGCP

Sui,Cong; Liu,Debao; Hu,Yong; Zhang,Linlin

doi:10.3892/etm.2019.7171

MicroRNA‑708‑5p affects proliferation and invasion of osteosarcoma cells by targeting URGCP

Authors:
- Cong Sui
- Debao Liu
- Yong Hu
- Linlin Zhang
View Affiliations

Affiliations: Department of Orthopedics, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230032, P.R. China, Department of Orthopaedics, The First Affiliated Hospital of University of Science and Technology of China, Hefei, Anhui 230001, P.R. China
Published online on: January 15, 2019 https://doi.org/10.3892/etm.2019.7171
Pages: 2235-2241
Copyright: © Sui et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Osteosarcoma is an aggressive cancer of the skeletal system which remains a challenge for the current therapeutic strategies due to unclear etiology and molecular mechanisms of pathogenesis. The current study aimed to determine the expression levels, role and molecular mechanism of microRNA‑708‑5p (miR‑708‑5p) in the development of osteosarcoma. The expression level of miR‑708‑5p was detected using reverse transcription‑quantitative polymerase chain reaction. miR‑708‑5p was overexpressed in SaOS‑2 cells using miR‑708‑5p mimics. Cell viability, apoptosis, migration and invasion were determined using Cell Counting kit‑8 assay, flow cytometry, wound healing and transwell assays, respectively. The results indicated that miR‑708‑5p was significantly downregulated in osteosarcoma tissues and cells, and its overexpression significantly inhibited cell viability, invasion and migration and induced apoptosis of SaOS‑2 cells. Furthermore, the present results indicated that miR‑708‑5p directly targeted the 3'‑untranslated region of up‑regulator of cell proliferation (URGCP) and negatively regulated its expression in SaOS‑2 cells. Taken together, the current study suggested that miR‑708‑5p may inhibit the growth and invasion of osteosarcoma cells via regulating the URGCP/NF‑κB signaling pathway. Further research on these molecules in osteosarcoma may provide novel insights into the target therapy for this disease.

View Figures

View References

1	Li X, Lu Q, Xie W, Wang Y and Wang G: Anti-tumor effects of triptolide on angiogenesis and cell apoptosis in osteosarcoma cells by inducing autophagy via repressing Wnt/β-Catenin signaling. Biochem Biophys Res Commun. 496:443–449. 2018. View Article : Google Scholar : PubMed/NCBI
2	Lo YC, Lin YC, Huang YF, Hsieh CP, Wu CC, Chang IL, Chen CL, Cheng CH and Chen HY: Carnosol-induced ROS inhibits cell viability of human osteosarcoma by apoptosis and autophagy. Am J Chin Med. 45:1761–1772. 2017. View Article : Google Scholar : PubMed/NCBI
3	Liu ZR, Sun LZ, Jia TH and Jia DF: β-Aescin shows potent antiproliferative activity in osteosarcoma cells by inducing autophagy, ROS generation and mitochondrial membrane potential loss. J BUON. 22:1582–1586. 2017.PubMed/NCBI
4	Xu HY, Fang W, Huang ZW, Lu JC, Wang YQ, Tang QL, Song GH, Kang Y, Zhu XJ, Zou CY, et al: Metformin reduces SATB2-mediated osteosarcoma stem cell-like phenotype and tumor growth via inhibition of N-cadherin/NF-kB signaling. Eur Rev Med Pharmacol Sci. 21:4516–4528. 2017.PubMed/NCBI
5	Shaikh AB, Li F, Li M, He B, He X, Chen G, Guo B, Li D, Jiang F, Dang L, et al: Present advances and future perspectives of molecular targeted therapy for osteosarcoma. Int J Mol Sci. 17:5062016. View Article : Google Scholar : PubMed/NCBI
6	Hu L, Ai J, Long H, Liu W, Wang X, Zuo Y, Li Y, Wu Q and Deng Y: Intergrative microRNA and gene profiling data analysis reveals novel biomarkers and mechanisms for lung cancer. Oncotarget. 7:8441–8454. 2016.PubMed/NCBI
7	Tsai MM, Wang CS, Tsai CY, Huang HW, Chi HC, Lin YH, Lu PH and Lin KH: Potential diagnostic, prognostic and therapeutic targets of microRNAs in human gastric cancer. Int J Mol Sci. 17:E9452016. View Article : Google Scholar : PubMed/NCBI
8	Zhao H, Li M, Li L, Yang X, Lan G and Zhang Y: MiR-133b is down-regulated in human osteosarcoma and inhibits osteosarcoma cells proliferation, migration and invasion, and promotes apoptosis. PLoS One. 8:e835712013. View Article : Google Scholar : PubMed/NCBI
9	Kaukoniemi KM, Rauhala HE, Scaravilli M, Latonen L, Annala M, Vessella RL, Nykter M, Tammela TL and Visakorpi T: Epigenetically altered miR-193b targets cyclin D1 in prostate cancer. Cancer Med. 4:1417–1425. 2015. View Article : Google Scholar : PubMed/NCBI
10	Zimmerman AL and Wu S: MicroRNAs, cancer and cancer stem cells. Cancer Lett. 300:10–19. 2011. View Article : Google Scholar : PubMed/NCBI
11	Schwarzenbacher D, Balic M and Pichler M: The role of microRNAs in breast cancer stem cells. Int J Mol Sci. 14:14712–14723. 2013. View Article : Google Scholar : PubMed/NCBI
12	Bartel DP: MicroRNAs: Target recognition and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
13	Friedman JM and Jones PA: MicroRNAs: Critical mediators of differentiation, development and disease. Swiss Med Wkly. 139:466–472. 2009.PubMed/NCBI
14	Schneider MR: MicroRNAs as novel players in skin development, homeostasis and disease. Br J Dermatol. 166:22–28. 2012. View Article : Google Scholar : PubMed/NCBI
15	Coghlin C and Murray GI: Current and emerging concepts in tumour metastasis. J Pathol. 222:1–15. 2010. View Article : Google Scholar : PubMed/NCBI
16	Zhang Y, Kim J, Mueller AC, Dey B, Yang Y, Lee DH, Hachmann J, Finderle S, Park DM, Christensen J, et al: Multiple receptor tyrosine kinases converge on microRNA-134 to control KRAS, STAT5B, and glioblastoma. Cell Death Differ. 21:720–734. 2014. View Article : Google Scholar : PubMed/NCBI
17	Garg M: Emerging role of microRNAs in cancer stem cells: Implications in cancer therapy. World J Stem Cells. 7:1078–1089. 2015. View Article : Google Scholar : PubMed/NCBI
18	Kloosterman WP and Plasterk RH: The diverse functions of microRNAs in animal development and disease. Dev Cell. 11:441–450. 2006. View Article : Google Scholar : PubMed/NCBI
19	Bicker S and Schratt G: microRNAs: Tiny regulators of synapse function in development and disease. J Cell Mol Med. 12:1466–1476. 2008. View Article : Google Scholar : PubMed/NCBI
20	Condorelli G and Dimmeler S: MicroRNAs: Components of an integrated system controlling cardiac development, physiology, and disease pathogenesis. Cardiovasc Res. 79:551–552. 2008. View Article : Google Scholar : PubMed/NCBI
21	He X, Eberhart JK and Postlethwait JH: MicroRNAs and micromanaging the skeleton in disease, development and evolution. J Cell Mol Med. 13:606–618. 2009. View Article : Google Scholar : PubMed/NCBI
22	Chhabra R and Saini N: MicroRNAs in cancer stem cells: Current status and future directions. Tumour Biol. 35:8395–8405. 2014. View Article : Google Scholar : PubMed/NCBI
23	Liu M, Lu S, He W, Zhang L, Ma Y, Lv P, Ma M, Yu W, Wang J, Zhang M, et al: ULK1-regulated autophagy: A mechanism in cellular protection for ALDH2 against hyperglycemia. Toxicol Lett. 283:106–115. 2018. View Article : Google Scholar : PubMed/NCBI
24	Ji Q, Karnak D, Hao P, Wang R and Xu L: No small matter: MicroRNAs - key regulators of cancer stem cells. Int J Clin Exp Med. 3:84–87. 2010.PubMed/NCBI
25	Nimmo RA and Slack FJ: An elegant miRror: MicroRNAs in stem cells, developmental timing and cancer. Chromosoma. 118:405–418. 2009. View Article : Google Scholar : PubMed/NCBI
26	Meng F, Glaser SS, Francis H, DeMorrow S, Han Y, Passarini JD, Stokes A, Cleary JP, Liu X, Venter J, et al: Functional analysis of microRNAs in human hepatocellular cancer stem cells. J Cell Mol Med. 16:160–173. 2012. View Article : Google Scholar : PubMed/NCBI
27	Xia H and Hui KM: MicroRNAs involved in regulating epithelial-mesenchymal transition and cancer stem cells as molecular targets for cancer therapeutics. Cancer Gene Ther. 19:723–730. 2012. View Article : Google Scholar : PubMed/NCBI
28	Shen Y, Pan Y, Xu L, Chen L, Liu L, Chen H, Chen Z and Meng Z: Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells. Tumour Biol. 36:4525–4534. 2015. View Article : Google Scholar : PubMed/NCBI
29	Huang YH, Yang YL, Huang FC, Tiao MM, Lin YC, Tsai MH and Wang FS: MicroRNA-29a mitigation of endoplasmic reticulum and autophagy aberrance counteracts in obstructive jaundice-induced fibrosis in mice. Exp Boil Med (Maywood). 243:13–21. 2018. View Article : Google Scholar
30	Tian J, An X and Niu L: Role of microRNAs in cardiac development and disease. Exp Ther Med. 13:3–8. 2017. View Article : Google Scholar : PubMed/NCBI
31	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
32	Yang J and Zhang W: New molecular insights into osteosarcoma targeted therapy. Curr Opin Oncol. 25:398–406. 2013. View Article : Google Scholar : PubMed/NCBI
33	Tsuchiya H, Tomita K, Mori Y, Asada N, Morinaga T, Kitano S and Yamamoto N: Caffeine-assisted chemotherapy and minimized tumor excision for nonmetastatic osteosarcoma. Anticancer Res. 18:657–666. 1998.PubMed/NCBI
34	Croce CM: Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet. 10:704–714. 2009. View Article : Google Scholar : PubMed/NCBI
35	Magri F, Vanoli F and Corti S: miRNA in spinal muscular atrophy pathogenesis and therapy. J Cell Mol Med. 22:755–767. 2018.PubMed/NCBI
36	Romakina VV, Zhirov IV, Nasonova SN, Zaseeva AV, Kochetov AG, Liang OV and Tereshchenko SN: MicroRNAs as biomarkers of cardiovascular diseases. Kardiologiia. 66–71. 2018.(In Russian). View Article : Google Scholar : PubMed/NCBI
37	Tian K, Wang L, Di R, Xu J, Li G and Li Z: Effect and mechanism of miRNA to osteosarcoma cell. Pak J Pharm Sci. 27 (5 Suppl):1657–1660. 2014.PubMed/NCBI
38	Xie B, Li Y, Zhao R, Xu Y, Wu Y, Wang J, Xia D, Han W and Chen D: Identification of key genes and miRNAs in osteosarcoma patients with chemoresistance by bioinformatics analysis. Biomed Res Int. 2018:47610642018. View Article : Google Scholar : PubMed/NCBI
39	Wu X, Liu T, Fang O, Dong W, Zhang F, Leach L, Hu X and Luo Z: MicroRNA-708-5p acts as a therapeutic agent against metastatic lung cancer. Oncotarget. 7:2417–2432. 2016.PubMed/NCBI
40	Yang J, Wei J, Wu Y, Wang Z, Guo Y, Lee P and Li X: Metformin induces ER stress-dependent apoptosis through miR-708-5p/NNAT pathway in prostate cancer. Oncogenesis. 4:e1582015. View Article : Google Scholar : PubMed/NCBI
41	Dodurga Y, Seçme M and Lale Şatıroğlu-Tufan N: A novel oncogene URG4/URGCP and its role in cancer. Gene. 668:12–17. 2018. View Article : Google Scholar : PubMed/NCBI
42	Yu G, Zhang T, Jing Y, Bao Q, Tang Q and Zhang Y: miR-519 suppresses nasopharyngeal carcinoma cell proliferation by targeting oncogene URG4/URGCP. Life Sci. 175:47–51. 2017. View Article : Google Scholar : PubMed/NCBI
43	Tokay E and Kockar F: Identification of intracellular pathways through which TGF-β1 upregulates URG-4/URGCP gene expression in hepatoma cells. Life Sci. 144:121–128. 2016. View Article : Google Scholar : PubMed/NCBI
44	Dodurga Y, Seçme M, Eroğlu C, Gündoğdu G, Avcı ÇB, Bağcı G, Küçükatay V and Lale Şatıroğlu-Tufan N: Investigation of the effects of a sulfite molecule on human neuroblastoma cells via a novel oncogene URG4/URGCP. Life Sci. 143:27–34. 2015. View Article : Google Scholar : PubMed/NCBI
45	Cai J, Li R, Xu X, Zhang L, Wu S, Yang T, Fang L, Wu J, Zhu X, Li M and Huang Y: URGCP promotes non-small cell lung cancer invasiveness by activating the NF-κB-MMP-9 pathway. Oncotarget. 6:36489–36504. 2015. View Article : Google Scholar : PubMed/NCBI
46	Wu M, Chen J, Wang Y, Hu J, Liu C, Feng C and Zeng X: URGCP/URG4 promotes apoptotic resistance in bladder cancer cells by activating NF-κB signaling. Oncotarget. 6:30887–30901. 2015.PubMed/NCBI
47	Xing S, Zhang B, Hua R, Tai WC, Zeng Z, Xie B, Huang C, Xue J, Xiong S, Yang J, et al: URG4/URGCP enhances the angiogenic capacity of human hepatocellular carcinoma cells in vitro via activation of the NF-κB signaling pathway. BMC Cancer. 15:3682015. View Article : Google Scholar : PubMed/NCBI